(Q43210150)

English

Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion

scientific article published in January 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

1 reference

based on heuristic

inferred from title

chronic hepatitis B

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Yuan-Hung Kuo

1

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Chien-Hung Chen

2

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Jing-Houng Wang

3

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Chou-Hung Hung

4

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Po-Lin Tseng

5

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Sheng-Nan Lu

6

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Chi-Sin Changchien

7

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Chuan-Mo Lee

8

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

publication date

1 January 2010

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Scandinavian Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

45

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

75-81

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Hepatitis B: global importance and need for control

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Management of hepatitis B: 2000--summary of a workshop

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Current therapeutic trends in therapy for chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Durability of serologic response after lamivudine treatment of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Determinants for sustained HBeAg response to lamivudine therapy

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy.

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Hepatitis B virus immunopathogenesis

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Lamivudine therapy of WHV-infected woodchucks.

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

1 reference

https://api.crossref.org/works/10.3109%2F00365520903394550

21 January 2018

Identifiers

10.3109/00365520903394550

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43210150&oldid=1983879345"